PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed
in critically ill patients with severe infections. These patients show several
pathophysiological changes that may alter the carbapenem pharmacokinetic (PK) normally found
in other populations. Although the PK of carbapenems has been widely studied, most studies
have been conducted on small populations, and clinical outcome data are sparse. Therefore,
the aims of this study are (i) describe the population pharmacokinetic parameters of
meropenem and imipenem in critically ill subject (ii) evaluate the pharmacodynamic of
meropenem and imipenem as a predictor of clinical treatment outcome.